Extended Safety, Immunogenicity and Efficacy of a Blood-Stage Malaria Vaccine in Malian Children: 24-Month Follow-Up of a Randomized, Double-Blinded Phase 2 Trial

BACKGROUND: The FMP2.1/AS02(A) candidate malaria vaccine was tested in a Phase 2 study in Mali. Based on results from the first eight months of follow-up, the vaccine appeared well-tolerated and immunogenic. It had no significant efficacy based on the primary endpoint, clinical malaria, but marginal...

Descripción completa

Detalles Bibliográficos
Autores principales: Laurens, Matthew B., Thera, Mahamadou A., Coulibaly, Drissa, Ouattara, Amed, Kone, Abdoulaye K., Guindo, Ando B., Traore, Karim, Traore, Idrissa, Kouriba, Bourema, Diallo, Dapa A., Diarra, Issa, Daou, Modibo, Dolo, Amagana, Tolo, Youssouf, Sissoko, Mahamadou S., Niangaly, Amadou, Sissoko, Mady, Takala-Harrison, Shannon, Lyke, Kirsten E., Wu, Yukun, Blackwelder, William C., Godeaux, Olivier, Vekemans, Johan, Dubois, Marie-Claude, Ballou, W. Ripley, Cohen, Joe, Dube, Tina, Soisson, Lorraine, Diggs, Carter L., House, Brent, Bennett, Jason W., Lanar, David E., Dutta, Sheetij, Heppner, D. Gray, Plowe, Christopher V., Doumbo, Ogobara K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3832522/
https://www.ncbi.nlm.nih.gov/pubmed/24260195
http://dx.doi.org/10.1371/journal.pone.0079323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3832522/
https://www.ncbi.nlm.nih.gov/pubmed/24260195
http://dx.doi.org/10.1371/journal.pone.0079323

Ejemplares similares